EXHIBIT 10.2Option Agreement • March 30th, 2001 • Page Active Holdings Inc / • Non-operating establishments • California
TO THE LICENSE AGREEMENTLicense Agreement • January 7th, 2009 • Proteo Inc • Non-operating establishments
AGREEMENT ---------Preferred Stock Purchase Agreement • June 11th, 2008 • Proteo Inc • Non-operating establishments • California
AGREEMENT ---------Common Stock Purchase Agreement • December 22nd, 2006 • Proteo Inc • Non-operating establishments • Nevada
SHELL ACQUISITION AGREEMENT This SHELL ACQUISITION AGREEMENT dated as of December 28, 2001 (this Agreement) is by and between Trivantage Group, Inc., a Nevada corporation (TVGE), Sitestar corporation, a shareholder of TVGE which is the owner of...Acquisition Agreement • February 20th, 2002 • Proteo Inc • Non-operating establishments • California
PROTEO, INC. COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • March 3rd, 2020 • Proteo Inc • Pharmaceutical preparations • California
This Common Stock Purchase Agreement (“Agreement”) is made this 29th day of February, 2020 by and between PROTEO, INC., a Nevada corporation with its principal place of business at 2102 Business Center Drive, Irvine, CA 92612 (the “Company”) and the Purchaser of its stock, Diethelm Siebuhr, Babentwiete 12, Großhansdorf, Germany (“Purchaser”).
LICENSE AGREEMENTLicense Agreement • August 3rd, 2011 • Proteo Inc • Non-operating establishments
This agreement, entered into effective as of December 30, 2000, by and between Proteo, Inc., a Nevada Corporation having its principal place of business at 2775 Mesa Verde Drive East, #F101, Costa Mesa, California 92626 (hereinafter the "Licensee"), and Professor Dr. med. Oliver Wiedow, MD, living at Forstweg 55, D-24105 Kiel, Germany,(hereinafter the "Licensor").
Re: Elafin License AgreementElafin License Agreement • March 29th, 2013 • Proteo Inc • Non-operating establishments
This is to confirm certain agreements and understandings reached between me and Proteo, Inc. in December 2012 based on the following background:
Contract for an Atypical Silent PartnershipContract for an Atypical Silent Partnership • November 3rd, 2011 • Proteo Inc • Non-operating establishments
The Owner operates a commercial business in Kiel. The purpose of the entrepreneur is the development, manufacturing and marketing of pharmaceuticals. Prof. Wiedow intends to participate as an atypical silent partner (in the meaning of §§ 230 et. seq. of the German Commercial Code) in the business of the Owner in order to strengthen the equity. To that end the parties agree as follows:
EXHIBIT 10Employment Agreement • April 25th, 2000 • Page Active Holdings Inc / • Non-operating establishments • Florida
Prof. Dr. med. Oliver Wiedow, Forstweg 55, D-24105 Kiel, GermanyElafin License Agreement • August 5th, 2019 • Proteo Inc • Pharmaceutical preparations
LICENSE AGREEMENTLicense Agreement • November 3rd, 2011 • Proteo Inc • Non-operating establishments
This agreement, entered into effective as of December 30, 2000, by and between Proteo, Inc., a Nevada Corporation having its principal place of business at 2775 Mesa Verde Drive East, #F101, Costa Mesa, California 92626 (hereinafter the "Licensee"), and Professor Dr. med. Oliver Wiedow, MD, living at Forstweg 55, D-24105 Kiel, Germany,(hereinafter the "Licensor").
FORBEARANCE AGREEMENT AND GENERAL RELEASEForbearance Agreement • November 3rd, 2011 • Proteo Inc • Non-operating establishments • California
THIS FORBEARANCE AGREEMENT AND GENERAL RELEASE (“Agreement”), dated as of July 6th, 2009, is entered by and among FIDEsprit AG, a Swiss corporation (“ Borrower ”), Axel J. Kutscher (“ Guarantor ”) and Proteo, Inc., a Nevada corporation (“ Proteo ” and together with Borrower and Guarantor, the “ Parties ”), with reference to the facts as set forth in the Recitals:
Prof. Dr. med. Oliver Wiedow Forstweg 55 D-24105 KielElafin License Agreement • August 18th, 2014 • Proteo Inc • Non-operating establishments
Prof. Dr. med. Oliver Wiedow, Forstweg 55, D-24105 Kiel, GermanyElafin License Agreement • November 14th, 2019 • Proteo Inc • Pharmaceutical preparations
ARTICLE III REPRESENTATIONS AND WARRANTIESShare Exchange Agreement • May 6th, 2002 • Proteo Inc • Non-operating establishments
Prof. Dr. med. Oliver Wiedow, Forstweg 55, D-24105 Kiel, GermanyElafin License Agreement • May 15th, 2017 • Proteo Inc • Pharmaceutical preparations
Agreement on the Assumption of DebtAgreement on the Assumption of Debt • February 17th, 2010 • Proteo Inc • Non-operating establishments
FID Esprit AG, Schlyffistrasse 17f, 8806 Bäch (SZ), CH owes to the creditor an amount of US$ 1,803,631.85 under that certain promissory note dating from June 9, 2008, in the original principal amount of US$3,600,000, issued in connection with that certain PREFERRED STOCK PURCHASE AGREEMENT dating from June 9, 2008, as modified by that certain Forbearance Agreement dating from July 6th, 2009. In place of FID Esprit AG the new debtor hereby assumes without consideration and without any benefits in return the obligations of FID Esprit AG resulting from the abovementioned agreements vis-à-vis the creditor; the creditor consents to this assumption of debt with discharging effect on FID Esprit AG. The GUARANTOR for the debt of the FID Esprit consents to the assumption of debt and expressly acknowledges, agrees and consents to the continuing validity of his guaranty of the unpaid principal amount of the promissory note in favour of the Creditor.
Att: Chief Executive OfficerElafin License Agreement • November 3rd, 2011 • Proteo Inc • Non-operating establishments
This is to confirm certain agreements and understandings reached between me and Proteo, Inc. in December 2010 based on the following background:
Confidential information has been omitted from portions of this document, indicated by [*], and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to this omitted information. AGREEMENTConfidentiality Agreement • May 22nd, 2014 • Proteo Inc • Non-operating establishments
This agreement (the “Agreement”) is made as of May 16, 2014 (the “Effective Date”) by and between Proteo Biotech AG, Am Kiel-Kanal 44, 24106 Kiel, Germany, (“Proteo”); and Biotech Development Corp,1393 Bennett Circle, Farmington, UT 84025, USA, a Nevada corporation, (“BDC”). Proteo and BDC are referred to individually and collectively as a “Party” or the “Parties.”
FORBEARANCE AGREEMENT AND GENERAL RELEASEForbearance Agreement • July 8th, 2009 • Proteo Inc • Non-operating establishments • California
THIS FORBEARANCE AGREEMENT AND GENERAL RELEASE (“Agreement”), dated as of July 6th, 2009, is entered by and among FIDEsprit AG, a Swiss corporation (“Borrower”), Axel J. Kutscher (“Guarantor”) and Proteo, Inc., a Nevada corporation (“Proteo” and together with Borrower and Guarantor, the “Parties”), with reference to the facts as set forth in the Recitals:
Re: Elafin License AgreementElafin License Agreement • March 27th, 2012 • Proteo Inc • Non-operating establishments
This is to confirm certain agreements and understandings reached between me and Proteo, Inc. in December 2011 based on the following background:
PROTEO, INC. PREFERRED STOCK PURCHASE AGREEMENTPreferred Stock Purchase Agreement • February 26th, 2014 • Proteo Inc • Non-operating establishments • California
This Preferred Stock Purchase Agreement ("Agreement") is made this _____ day of______, 20___ by and between PROTEO, INC., a Nevada corporation with its principal place of business at 2102 Business Center Drive, Irvine, CA 92612 (the "Company") and the Purchaser of its stock, ______________ ("Purchaser").
EXHIBIT 10.7License Agreement • November 14th, 2007 • Proteo Inc • Non-operating establishments
PROTEO, INC. PREFERRED STOCK PURCHASE AGREEMENTPreferred Stock Purchase Agreement • April 11th, 2019 • Proteo Inc • Pharmaceutical preparations • California
This Preferred Stock Purchase Agreement (“Agreement”) is made this tenth (10th ) day of April, 2019 by and between PROTEO, INC., a Nevada corporation with its principal place of business at 2102 Business Center Drive, Irvine, CA 92612 (the “Company”), and the purchaser of its stock, SENATUS AG, a Swiss corporation with its principal place of business at Rorschacher Str. 302, CH-9016 St. Gallen (“Purchaser”).
PROTEO, INC. PREFERRED STOCK PURCHASE AGREEMENTPreferred Stock Purchase Agreement • September 13th, 2016 • Proteo Inc • Pharmaceutical preparations • California
This Preferred Stock Purchase Agreement (“Agreement”) is made this ninth (9th) day of September, 2016 by and between PROTEO, INC., a Nevada corporation with its principal place of business at 2102 Business Center Drive, Irvine, CA 92612 (the “Company”), and the purchaser of its stock, CFI Innovation GmbH Berlin Unternehmensberatung und Beteiligungen, a German corporation with its principal place of business at Normannenstraße 4, 14129 Berlin, Germany (“Purchaser”).
PROTEO, INC. PREFERRED STOCK PURCHASE AGREEMENTPreferred Stock Purchase Agreement • November 3rd, 2011 • Proteo Inc • Non-operating establishments • California
This Preferred Stock Purchase Agreement ("Agreement") is made this 9th day of June, 2008 by and between PROTEO, INC., a Nevada corporation with its principal place of business at 2102 Business Center Drive, Irvine, CA 92612 (the "Company") and the Purchaser of its stock, FIDEsprit AG, a Swiss corporation with its principal place of business at Rosengartenstr. 4, CH-8608 Bubikon, Switzerland ("Purchaser").
